The first peer-reviewed video demonstrating an implantable cardioverter-defibrillator (ICD) implantation has been published in JoVE, the Journal of Visualized Experiments. The procedure was performed by professor Dietmar Bänsch at University Hospital of Rostok, Germany. Bänsch used the implantable cardioverter-defibrillator Lumax VR-T DX (Biotronik).
JoVE was established as a new tool in life science publication and is the first scientific video journal for biological, medical, chemical and physical research.
During the video footage, Bänsch describes the diagnosis and assessment of a 40-year-old female patient and the implantation of the Lumax VR-T DX defibrillator with a Linoxsmart S DX lead. The entire implantation process, from lead insertion and assessment through administering a test shock, can be viewed in the video.
“Demonstrating the implantation visually in JoVE means the viewer can see every single step of the implantation process, including the visual aids that were used when positioning the lead, and can follow all the measurements while every step is explained,” Bänsch reported.
“This audiovisual demonstration is an exceptionally beneficial tool for clinical education,” he continued. “For the viewer, it is like standing in the operating room. During the implantation, you can clearly see what makes the Lumax VR-T DX unique. It is a single-chamber ICD that provides complete atrial and ventricular diagnostics.”
Complete diagnostics result from a specially designed Linoxsmart S DX ICD lead that is implanted in the same way as a standard single-chamber ICD lead. A floating atrial dipole senses signals coming from the atrial chambers of the patient’s heart, and the complementary atrial information ensures accurate diagnostic capabilities and unique protection for single-chamber ICD patients.
“The Lumax VR-T DX gives physicians access to complete atrial fibrillation and heart failure diagnostic data, which, alongside Biotronik Home Monitoring, significantly improve the early detection of atrial fibrillation and reduce any inappropriate therapies,” Bänsch added.
